Inactive Instrument

Wound Management Technologies Inc Share Price Other OTC

Equities

US98211X1063

Pharmaceuticals

Sales 2024 * 7.73Cr 644.68Cr Sales 2025 * 8.86Cr 738.92Cr Capitalization 24Cr 2.03TCr
Net income 2024 * -60L -50Cr Net income 2025 * -10L -8.34Cr EV / Sales 2024 * 3.15 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 2.75 x
P/E ratio 2024 *
-35.7 x
P/E ratio 2025 *
-257 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 39.54%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Wound Management Technologies Inc

Managers TitleAgeSince
Director of Finance/CFO 59 11/18/11
Chief Tech/Sci/R&D Officer - 01/23/01
Chief Tech/Sci/R&D Officer 39 01/21/01
Members of the board TitleAgeSince
Director/Board Member 55 01/22/01
Director/Board Member 57 01/22/01
Director/Board Member 55 01/23/01
More insiders
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. It markets several products for surgical and chronic wound care applications and has multiple products in its pipeline. Its surgical products, CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus Advanced Viable Bone Matrix (ALLOCYTE Plus), BIASURGE, FORTIFY TRG Tissue Repair Graft (FORTIFY TRG), and FORTIFY FLOWABLE Extracellular Matrix (FORTIFY FLOWABLE) are used in a range of surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products, FORTIFY TRG and FORTIFY FLOWABLE are used in specialties, including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and others.
Related indices
More about the company